Effects of a New Combination of Nutraceuticals with Morus alba on Lipid Profile, Insulin Sensitivity and Endotelial Function in Dyslipidemic Subjects. A Cross-Over, Randomized, Double-Blind Trial

[1]  A. D'Angelo,et al.  Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. , 2015, Atherosclerosis.

[2]  G. Marchesini,et al.  Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes , 2013, Clinical pharmacology : advances and applications.

[3]  Chunhua Wang,et al.  Antidiabetic and Antioxidant Effects and Phytochemicals of Mulberry Fruit (Morus alba L.) Polyphenol Enhanced Extract , 2013, PloS one.

[4]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[5]  P. Gargiulo,et al.  Endothelial dysfunction in type 2 diabetic patients with normal coronary arteries: a digital reactive hyperemia study. , 2013, International journal of cardiology.

[6]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[7]  T. Stijnen,et al.  Insulin Resistance and Risk of Incident Cardiovascular Events in Adults without Diabetes: Meta-Analysis , 2012, PloS one.

[8]  P. Gargiulo,et al.  Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[10]  Ian Graham,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[11]  L. Saccá,et al.  Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[12]  Xiaolan Yang,et al.  Hypolipidemic and antioxidant effects of mulberry (Morus alba L.) fruit in hyperlipidaemia rats. , 2010, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[13]  Raffaele Izzo,et al.  Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia , 2010, Journal of hypertension.

[14]  S. Rodriguez-Segade,et al.  Translating the A1C Assay Into Estimated Average Glucose Values , 2009, Diabetes Care.

[15]  D. Schoenfeld,et al.  Translating the A1C Assay Into Estimated Average Glucose Values , 2008, Diabetes Care.

[16]  Peter Libby,et al.  The forgotten majority: unfinished business in cardiovascular risk reduction. , 2005, Journal of the American College of Cardiology.

[17]  C. van Weel,et al.  Alpha-glucosidase inhibitors for type 2 diabetes mellitus. , 2005, The Cochrane database of systematic reviews.

[18]  N. Day,et al.  Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.

[19]  S. Julious.  Sample sizes for clinical trials with Normal data , 2004, Statistics in medicine.

[20]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.